GoKawiilThank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Author Correction: SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer
Why This Matters
This correction highlights the importance of accurate scientific communication in the development of immunotherapies targeting SLAMF6, a key regulator of T cell immunity against cancer. Understanding and refining these findings can accelerate the creation of more effective cancer treatments, benefiting both the industry and patients. Precise research ensures that innovative therapies are based on reliable data, ultimately advancing personalized medicine.
Key Takeaways
- SLAMF6 is identified as a drug-targetable suppressor of T cell immunity.
- Accurate scientific corrections are crucial for advancing cancer immunotherapy research.
- Improved understanding of T cell regulation can lead to more effective cancer treatments.
Get alerts for these topics